ArticleClinical trials (London, England)2025

Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial.

Sheila Kansiime et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.